Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine/Naloxone Abuse Liability Study
NCT00000329Phase 2Withdrawn
- Sponsor
- University of Colorado Denver
- Start
- Apr 1999
- Primary completion
- Aug 1999
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of buprenorphine + naloxone in opioid use disorder (OUD) (2 arms), sponsored by University of Colorado Denver. Primary endpoints: Subjective dose estimate, Observed withdrawal rating and 6 more. Planned start Apr 1999; status: withdrawn.
02
Drugs
buprenorphine + naloxone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT00000329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000329.